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1561-5413/Copyright ª 2015, Hong KoAbstract Staphylococcal immunoglobulin A (IgA)-dominant infection-related glomerulone-
phritis (IgA-IRGN) is an emerging clinical entity seen in immunocompromised hosts. Antibiotics
are the mainstay of treatment and the role of steroids is controversial. We present a review of
literature and our recommendations on the use of steroids in the management of IgA-IRGN.
近年來，葡萄球菌感染相關的 IgA 型腎小球腎炎 (IgA-IRGN) 逐漸被世人認識，通常發生於免疫機
能不全的病人，治療以抗生素療法為主，類固醇的角色則仍然存有爭議。以下我們將回顧
IgA-IRGN 的相關文獻，並對此病的臨床處置作出建議。Introduction
Nasr and colleagues1 introduced the term “immunoglobulin
A (IgA)-dominant postinfectious glomerulonephritis” in the
year 2003. The causative infection is often ongoing at the
time of diagnosis, hence, the term IgA-dominant infection-
related glomerulonephritis (IgA-IRGN) is preferable.2 IgA-
IRGN may be caused by Staphylococcus including
methicillin-resistant Staphylococcus aureus (MRSA),3
Streptococcus, and Gram-negative bacteria4 with variable
sites of infection and has a predilection for elderly, dia-
betic, and immunocompromised hosts.5 Most of the case
reports have been reported from the US, Japan, and
Taiwan.5 Diabetic patients with evidence of end organ
damage such as nephropathy, neuropathy, and peripheralof Nephrology, M.S. Ramaiah
R. Nagar, Bengaluru 560 054,
yahoo.co.in (M. Eswarappa).
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ng Society of Nephrology Ltd. Puvascular disease are at great risk of development of skin
ulcers with superimposed bacterial infection explaining the
increased incidence of IgA-IRGN in this population.1,6 There
are only a few case reports that focus on the treatment of
this entity. The role of steroids has been controversial with
regard to its indications, timing, and long-term complica-
tions including relapse of infection. The purpose of this
article is to review the literature regarding the role of
steroids in the management of this emerging clinical entity.
Pathogenesis
Koyama et al3 found that the serum levels of IgA and IgA
immune complexes were higher in patients with post-MRSA
glomerulonephritis than in patients without nephritis. They
speculated that staphylococcal enterotoxins may behave as
superantigens that can bind directly to major histocom-
patibility complex (MHC) class II molecules on antigen-
presenting cells. The enterotoxin-MHC class II complex
then binds to the T-cell receptor which results in massive T-
cell activation with cytokine burst, leading to B-cellblished by Elsevier Taiwan LLC. All rights reserved.
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new S. aureus envelope antigen termed “probable adhesin”
has been proposed to induce IgA formation.7 Cell wall com-
ponents of several strains of Gram-negative bacteria have
also been administered in mice experimental models to
induce glomerular IgA and complement 3 (C3) deposition.8
Clinical and histologic features that favor IgA-IRGN over
IgA nephropathy include initial presentation in older age,
acute renal failure at presentation, intercurrent culture-
documented staphylococcal infection, hypo-
complementemia, diffuse endocapillary hypercellularity
with prominent neutrophil infiltration on light microscopy,
stronger staining for C3 than IgA and lack of lambda pre-
dominance on immunofluorescence, and the presence of
subepithelial humps on electron microscopy.1,9e11Role of steroids
Due to lack of good quality trials, there is no robust data for
the use of steroids in IgA-IRGN. Given the immune-
mediated pathophysiology involving the interaction of the
host immune system with bacterial superantigens, the anti-
inflammatory and immunomodulatory effects of steroids







Yamashita et al22 1 58/M Pneumonia
Nagaba et al17 2 54/M Abdominal
abscess
23/M Skin abscess
Pola et al23 1 30/NA Septic arthritis
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Handa et al11 57/F Atopic dermatitis
Eswarappa et al14 1 70/M Pneumonia
HD Z hemodialysis; NA Z not available.
a One out of the eight patients studied was treated with steroids.
b One out of the two patients studied was treated with steroids.
c One out of the seven patients studied was treated with steroids.
d Four out of the seven patients were treated with steroids.flare up of underlying infection, especially in an immuno-
compromised host.
Okuyama et al13 suggest considering steroid use, only in
patients in whom the MRSA infection has definitely been
cured and whose glomerulonephritis symptoms do not
improve for weeks. Even in such instances, they advise
simultaneous antibiotic treatment. Kapadia et al12 pro-
posed similar recommendations for crescentic IRGN. We
described successful treatment of staphylococcal IgA-IRGN
with steroids alone in a patient who presented 6 weeks
after the onset of infection, at which time there was no
evidence of active infection.14 Chen and Wen15 reviewed 10
cases of MRSA-associated crescentic IgA-IRGN. In addition
to antibiotic treatment, steroids were administrated to five
patients. All patients achieved partial recovery of renal
function, however, two patients succumbed to infectious
complications (sepsis and cerebral bacterial embolism), 4
months after initiation of steroid therapy. The authors
echoed the suggestion given by Okuyama et al.13
Several authors16,17 do not support the use of steroids in
staphylococcal IgA-IRGN. They have suggested that steroids
should be avoided because of the increased risk of wors-
ening of the infections and that this type of glomerulone-
phritis may respond to antibiotic treatment alone in most
cases. One explanation for this suggestion could be thefection-related glomerulonephritis treated with steroids.
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48 M. Eswarappa et al.prolonged persistence of staphylococcal antigens and the
corresponding antibodies in host circulation despite
appropriate therapy.18 The decision to treat elderly pa-
tients with immunosuppressive therapy is more challenging
than treating poststreptococcal glomerulonephritis in chil-
dren, because the infection is frequently active at the time
of renal presentation and coexistent diabetes.2 The best
available data come from a retrospective observational
study19 of 109 elderly patients with bacterial IRGN, 46% of
whom had staphylococcal IgA-IRGN. Among the 98 patients
with available data, 22 patients with an elevated serum
creatinine with or without crescents were treated with
glucocorticoids for variable periods of time. Three patients
had a complete remission, 12 patients had a persistent
elevation in serum creatinine, seven patients progressed to
end-stage renal disease (ESRD), and four patients died. No
correlation was observed between glucocorticoid therapy
and renal outcomes. Similar lack of benefit has also been
noted in other observational studies of patients with bac-
terial IRGN.2,20,21 Published cases of staphylococcal IgA-
IRGN treated with steroids and their outcomes are sum-
marized in Table 1.
On the basis of the absence of proven benefit and the
potential risks in this population, Nasr et al2 recommend that
immunosuppressive therapy should not be used in most
adultswith staphylococcal IgA-IRGNand that active infection
should be eradicated using antibiotics, with surgery, if indi-
cated. Based on the data reviewed and our experience, we
suggest that a meticulous evaluation including a thorough
clinical examination and investigation (chest radiograph,
abdominal ultrasonogram, echocardiogram, appropriate
cultures) should be performed in all cases of IgA-IRGN to rule
out active infection before initiating steroids. Steroids may
be considered in IgA-IRGN in the following conditions: (1)
histologic evidence of >30% glomeruli with crescents or se-
vere acute interstitial nephritis or diffuse proliferative
glomerulonephritis pattern of injury with associated persis-
tent or progressive renal dysfunction; (2) those who do not
respond to antibiotic therapy alone with associated lack of
improvement or a progressive decline in renal function even
after 6 weeks of starting antibiotics; and (3) those with
nephrotic-range proteinuria. Concomitant use of antibiotic
therapy is strongly recommended.
We suggest using a short course of intravenous pulse
steroid therapy (500 mg to 1 g/1.73 m2 methylprednisolone
once daily) for 3 days, particularly for patients with rapidly
progressive renal failure. This may be followed by oral
prednisolone 0.5 mg/kg/d tapered over 3 weeks. Oral ste-
roids may suffice in other conditions mentioned above.
Limitations of our review include use of retrospective
data, low patient numbers, and lack of data on optimal
dose and duration of steroids.
In conclusion, patients with IgA-IRGN remain at risk for
chronic kidney disease and ESRD in cases of incomplete res-
olution of the inflammatory process. The risks of using ste-
roids should be carefully balanced against potential benefits.Conflicts of interest
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